Helicobacter Pylori Eradication Rate
Conditions
Keywords
Helicobacter pylori, Sequential therapy, Modified non-clarithromycin triple therapy
Brief summary
Helicobacter pylori (H. pylori) infects more than 50% of the population in the world(1), especially 47-66% in China.
Interventions
DRUGModified non-clarithromycin triple therapy
H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
Sponsors
Shandong University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients who were intend to undergo upper endoscopy for any purpose and volunteered to written inform consent.
Exclusion criteria
* negative in rapid urease test (RUT) * previous standard eradication therapy for H. pylori; * history of esophagectomy or gastrectomy; * gastrointestinal malignancy; * contraindications or allergic to study drugs; * user of taking medicine that may affect the result of the study within 4 weeks (e.g., proton-pump inhibitors, H2-receptor antagonists, bismuth or antibiotics etc.); * cardiopulmonary, hepatic or renal insufficiency, and/or severe current diseases or malignancy; * pregnant or lactating women; * participants of other trial within the past 3 months; * unwilling or unable to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the difference of eradication rates between 2 groups | 5 months |
Secondary
| Measure | Time frame |
|---|---|
| the different rates of adverse events between 2 groups | 5 months |
Countries
China
Outcome results
None listed